Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, announced that its Chairman and CEO, Keith Grossman, CFO Rod MacLeod, and CMO David Caraway will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on March 4, 2022, at 10:00 AM ET. The event will provide insights into Nevro's innovative solutions, including the proprietary 10 kHz Therapy. Investors can access a live webcast and archived recording on Nevro's website. For ongoing updates, Nevro encourages stakeholders to regularly visit their Investor Relations section.
Details
News Market Reaction – NVRO
The recorded move for NVRO in the trading session of this news was -1.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 18, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, Rod MacLeod, Chief Financial Officer, and Dr. David Caraway, Chief Medical Officer, will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on Friday, March 4, 2022 at 10:00 am Eastern Time.
A webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 80,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy.
Senza®, Senza II®, and Senza Omnia™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
Senza, Senza II, Senza Omnia, HFX, HXF Coach, HFX Cloud, HFX Connect, Nevro and the Nevro logo are trademarks of Nevro Corp.
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | julie.dewey@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-participate-in-wells-fargo-2022-medtech-rd-spotlight-call-series-301485517.html
SOURCE Nevro Corp.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.